Of the nearly 1.4 million new cases of breast cancer diagnosed each year, a large proportion is characterized as hormone receptor negative, lacking estrogen receptors (ER) and/or progesterone receptors (PR). Patients with receptor-negative tumors do not respond to current steroid hormone based therapies and generally have significantly higher risk of recurrence and mortality compared to patients with tumors that are ER- and/or PR-positive. Previous in vitro studies had shown that the progesterone metabolites, 5-dihydroprogesterone (5P) and 3-dihydroprogesterone (3HP), respectively, exhibit pro-cancer and anti-cancer effects on receptor-negative human breast cell lines. Here in vivo studies were conducted to investigate the ability of 5P and 3HP to control initiation, growth and regression of ER/PR-negative human breast cell tumors.
»
05/11/13